Retroviral intasome assembly and inhibition of DNA strand transfer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Integrase is an essential retroviral enzyme that binds both termini of linear viral DNA and inserts them into a host cell chromosome. The structure of full-length retroviral integrase, either separately or in complex with DNA, has been lacking. Furthermore, although clinically useful inhibitors of HIV integrase have been developed, their mechanism of action remains speculative. Here we present a crystal structure of full-length integrase from the prototype foamy virus in complex with its cognate DNA. The structure shows the organization of the retroviral intasome comprising an integrase tetramer tightly associated with a pair of viral DNA ends. All three canonical integrase structural domains are involved in extensive protein-DNA and protein-protein interactions. The binding of strand-transfer inhibitors displaces the reactive viral DNA end from the active site, disarming the viral nucleoprotein complex. Our findings define the structural basis of retroviral DNA integration, and will allow modelling of the HIV-1 intasome to aid in the development of antiretroviral drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The structures revealed unexpected architectural diversity among intasomes from different retroviral genera.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with their function, all intasomes feature 2-fold symmetry and harbour a pair of juxtaposed active sites engaged with 3’ vDNA ends.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Within the CIC, the IN dimers are bridged via the exchange of associated NTDs and are joined by a pair of CTDs (referred to as the synaptic CTDs), which act as rigid spacers.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the intasomes from the prototype foamy virus (PFV, a simiispumavirus) as well as the δ-retroviruses HTLV-1 and simian T-cell lymphotropic virus (STLV) contain four IN subunits (arranged as a dimer-of-dimers)25,29,37,38”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite these differences, all intasomes incorporate the conserved intasome core (CIC) assembly, which is the minimal functional unit and is represented by the PFV structure (Figs. 2A, 3).”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
The interpretation of protein structures: Estimation of static accessibility
Lee, B., & Richards, F. M. (1971) · Journal of Molecular Biology · doi:10.1016/0022-2836(71)90324-x · Cited by 5,850
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Buccaneer software for automated model building. 1. Tracing protein chains
Cowtan, K. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906022116 · Cited by 1,822
Use of TLS parameters to model anisotropic displacements in macromolecular refinement
Winn, M. D., Isupov, M. N., & Murshudov, G. N. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900014736 · Cited by 1,696
Gouet, P. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg556 · Cited by 1,509
Research works printed but not linked: 2
- Grobler, J. A., Stillmock, K., Miller, M. D. & Hazuda, D. J. Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir. Antivir. Ther. 13 (suppl. 3). A41 (2008)
- Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography no. 26, (1992)
Cited by
Items 201–300 of 719
Xue, W., Liu, H., & Yao, X. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.22887 · Cited by 39
HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation
Luca, L. D., Grazia, S. D., Ferro, S., Gitto, R., Christ, F., Debyser, Z., & Chimirri, A. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.12.012 · Cited by 40
“1) (pdb code 3L2T) [23] and the core domain of HIV-IN previously modeled by us (pdb code 1WKN) [18].”
InfluentialRaheem, I. T., Walji, A. M., Klein, D. J., Sanders, J. M., Powell, D. A., Abeywickrema, P. D., Barbe, G., Bennet, A., Clas, S., Dubost, D. C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01037 · Cited by 37
Esposito, F., Ambrosio, F. A., Maleddu, R., Costa, G., Rocca, R., Maccioni, E., Catalano, R., Romeo, I., Eleftheriou, P. T., Karia, D. C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111617 · Cited by 38
Cutting antiparallel DNA strands in a single active site
Chen, X., Cui, Y., Best, R. B., Wang, H., Zhou, Z. H., Yang, W., & Gellert, M. F. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0363-2 · Cited by 38
Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors
Smith, R. A., Gottlieb, G. S., & Miller, A. D. (2010) · Retrovirology · doi:10.1186/1742-4690-7-70 · Cited by 37
“inhibitors, based on a recent structural analysis of prototype foamy virus integrase [51].”
BackgroundMeasuring rapid hydrogen exchange in the homodimeric 36 kDa HIV‐1 integrase catalytic core domain
Fitzkee, N. C., Torchia, D. A., & Bax, A. (2011) · Protein Science · doi:10.1002/pro.582 · Cited by 38
“To interpret this in structural terms, we note that in the DNA-bound structure of PFV integrase, the amide of the corresponding residue (T210) is H-bonded to the OH of S216 (S147 in HIV-1 integrase).(27) Thus, the observation of high knoe values in the CCD strongly suggests that the catalytic loop in the absence of DN…”
BackgroundDesign of a series of bicyclic HIV-1 integrase inhibitors. Part 2: Azoles: Effective metal chelators
Le, G. T., Vandegraaff, N., Rhodes, D. I., Jones, E. D., Coates, J. A. V., Thienthong, N., Winfield, L. J., Lü, L., Li, X., Yu, C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.081 · Cited by 36
Meehan, A. M., Saenz, D. T., Morrison, J. H., Hu, C., Peretz, M., & Poeschla, E. M. (2011) · Journal of Virology · doi:10.1128/jvi.01295-10 · Cited by 38
Yin, Z., Lapkouski, M., Yang, W., & Craigie, R. (2012) · Protein Science · doi:10.1002/pro.2166 · Cited by 35
“Only the core domain of each outer subunit is traceable and forms the conserved dimer interface with the inner subunit, but the N-terminal and C-terminal domains are disordered as reported.(7,8) The viral and target DNAs in the STC are like four arms (two viral and two target) arranged in a tetrahedral configuration a…”
BackgroundStructural and Functional Role of INI1 and LEDGF in the HIV-1 Preintegration Complex
Maillot, B., Lévy, N., Eiler, S., Crucifix, C., Granger, F., Richert, L., Didier, P., Godet, J., Pradeau‐Aubreton, K., Emiliani, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060734 · Cited by 56
“Superimposition of the structures of the IN catalytic core domain of the Rous sarcoma virus (RSV) [74] in gold, HIV-1 [11] in red and PVF [72] in cyan.”
BackgroundInfluentialMK-0536 Inhibits HIV-1 Integrases Resistant to Raltegravir
Métifiot, M., Johnson, B. C., Smith, S. J., Zhao, X. Z., Marchand, C., Burke, T. R., Hughes, S. H., & Pommier, Y. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05288-11 · Cited by 37
“The crystal structure of PFV IN bound to an oligonucleotide mimicking the processed viral DNA end has been solved (6).”
BackgroundGupta, K., Curtis, J. E., Krueger, S., Hwang, Y., Cherepanov, P., Bushman, F. D., & Van Duyne, G. D. (2012) · Structure · doi:10.1016/j.str.2012.08.023 · Cited by 35
“Complexes were prepared as described previously (Hare et al., 2010).”
BackgroundMethodInfluentialSelf-citationSynthesis of dihydropyrimidine α,γ-diketobutanoic acid derivatives targeting HIV integrase
Sari, O., Roy, V., Métifiot, M., Marchand, C., Pommier, Y. G., Bourg, S., Bonnet, P., Schinazi, R. F., & Agrofoglio, L. A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.015 · Cited by 38
Underwood, M., Horton, J., Nangle, K., Hopking, J., Smith, K., Aboud, M., Wynne, B., Sievers, J., Stewart, E. L., & Wang, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01643-21 · Cited by 38
“that G118R model was based on the crystal structure of the prototype foamy virus integrase bound only to vDNA (37), the hydrogen bond between G118R and the tDNA sub-”
MethodApetroaei, M.-M., Velescu, B. Ș., Nedea, M. I., Dinu‐Pîrvu, C. E., Drăgănescu, D., Fâcă, A. I., Udeanu, D. I., & Arsene, A. L. (2024) · Biomedicines · doi:10.3390/biomedicines12040915 · Cited by 45
“…in antiretroviral drugs serves as an illustration of the complex dynamics of HIV viral evolution and emphasizes the necessity for an all-encompassing strategy that incorporates molecular investigation and the discovery of novel chemical structures that can be employed to address this phenomenon.”
BackgroundRetroviral intasomes search for a target DNA by 1D diffusion which rarely results in integration
Jones, N. D., Lopez, M. A., Hanne, J., Peake, M. B., Lee, J., Fishel, R. A., & Yoder, K. E. (2016) · Nature Communications · doi:10.1038/ncomms11409 · Cited by 34
Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
Multimodal Functionalities of HIV-1 Integrase
Engelman, A., & Kvaratskhelia, M. (2022) · Viruses · doi:10.3390/v14050926 · Cited by 41
“The PFV intasome comprises an IN tetramer that binds to and synapses the vDNA ends together.”
BackgroundInfluentialSelf-citationCellular Cofactors of Lentiviral Integrase: From Target Validation to Drug Discovery
Taltynov, O., Desimmie, B. A., Demeulemeester, J., Christ, F., & Debyser, Z. (2012) · Molecular Biology International · doi:10.1155/2012/863405 · Cited by 37
“Despite the recent release of the crystal structure of full-length IN of the prototype foamy virus (PFV) [29], we still lack a crystal structure of full-length HIV-1 IN.”
BackgroundGoethals, O., Ginderen, M. V., Vos, A. M., Cummings, M. D., der Borght, K. V., Wesenbeeck, L. V., Feyaerts, M., Verheyen, A., Smits, V., Loock, M. V., et al. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.05.011 · Cited by 38
“cognate DNA and MK-2048 solved by Hare et al. (2010b). The wild-type residues”
BackgroundDynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry
Borrenberghs, D., Dirix, L., Wit, F. D., Rocha, S., Blokken, J., Houwer, S. D., Gijsbers, R., Christ, F., Hofkens, J., Hendrix, J., et al. (2016) · Scientific Reports · doi:10.1038/srep36485 · Cited by 38
“We consider a scenario according to which IN first assembles on the vDNA ends 29 , after which the IN tetramer-vDNA ends complex engages LEDGF/p75 83 .”
MuLV IN mutants responsive to HDAC inhibitors enhance transcription from unintegrated retroviral DNA
Schneider, W. M., Wu, D.-T., Amin, V., Aiyer, S., & Roth, M. J. (2012) · Virology · doi:10.1016/j.virol.2012.01.034 · Cited by 33
“These results indicate that at least one acetylation site maps within the MuLV IN CTD. Characterization of MuLV IN mutants Sequence homology is low across the CTDs of various retroviral INs, however, structurebased sequence alignments between prototype foamy virus (PFV) (Hare et al., 2010b), HIV-1 (Chen et al., 2000;…”
BackgroundInfluentialWang, Z., Wang, M., Yao, X. X., Li, Y., Qiao, W., Geng, Y., Liu, Y., & Wang, Q. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.015 · Cited by 34
“Despite the lack of detailed structural information about HIV-1 IN/DNA interactions, this speculative mechanism of action tends to be validated by the recent X-ray crystal structure of integrase from the prototype foamy virus (PFV-1 IN) in complex with its cognate viral DNA and strand transfer inhibitors [12,13].”
BackgroundPatterns of resistance development with integrase inhibitors in HIV
Cane, P., Mbisa, J. L., & Martín (2011) · Infection and Drug Resistance · doi:10.2147/idr.s7775 · Cited by 41
Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited
Tang, J. Y., Maddali, K., Pommier, Y. G., Sham, Y. Y., & Wang, Z. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.048 · Cited by 33
Cryo-EM structure of the deltaretroviral intasome in complex with the PP2A regulatory subunit B56γ
Barski, M. S., Minnell, J. J., Hodakova, Z., Pye, V. E., Nans, A., Cherepanov, P., & Maertens, G. N. (2020) · Nature Communications · doi:10.1038/s41467-020-18874-y · Cited by 29
Self-citationHuang, M., Grant, G. H., & Richards, W. G. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.04.002 · Cited by 34
Different Pathways Leading to Integrase Inhibitors Resistance
Thierry, E., Deprez, E., & Delelis, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02165 · Cited by 40
“…(Hare et al., 2011), i.e., that the three coplanar oxygen atoms allow the Frontiers in Microbiology | www.frontiersin.org 4 January 2017 | Volume 7 | Article 2165 chelation of Mg2+ cations, while the halogenated group competes with the binding of the 3′-processed end (Hare et al., 2010a).”
BackgroundInfluentialThe Eurasian hot nightlife: Environmental forces associated with nocturnality in lizards
Vidan, E., Roll, U., Bauer, A. M., Grismer, L. L., Guo, P., Maza, E., Novosolov, M., Sindaco, R., Wagner, P., Belmaker, J., et al. (2017) · Global Ecology and Biogeography · doi:10.1111/geb.12643 · Cited by 33
Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors
Reddy, K. K., & Singh, S. K. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.04.011 · Cited by 32
Novel integrase inhibitors for HIV
Prada, N., & Markowitz, M. H. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.501078 · Cited by 30
“Detailed analysis of HIV-1 IN highly conserved residues [86] and the recently published crystal structure of the IN of prototype foamy virus [18] are relevant tools that will help the development of novel HIV-1 inhibitors with alternative mechanisms of action and resistance profiles.”
BackgroundMethodDiscovery of small molecule HIV-1 integrase dimerization inhibitors
Tintori, C., Demeulemeester, J., Franchi, L., Massa, S., Debyser, Z., Christ, F., & Botta, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.064 · Cited by 34
Bojja, R. S., Andrake, M. D., Weigand, S., Merkel, G., Yarychkivska, O., Henderson, A., Kummerling, M., & Skalka, A. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212571 · Cited by 29
Architecture and Assembly of HIV Integrase Multimers in the Absence of DNA Substrates
Bojja, R. S., Andrake, M., Merkel, G. W., Weigand, S. L., Dunbrack, R. L., & Skalka, A. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434431 · Cited by 30
“the crystal structure of the PFV intasome (2).”
BackgroundMethodInfluentialNon-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
Himmel, D. M., & Arnold, E. (2020) · Pharmaceuticals · doi:10.3390/ph13060122 · Cited by 32
“The dsDNA codes for two polyproteins (Gag and Gag-Pol) that contain the immature structural proteins (Gag) and the enzymes (Pol), which HIV PR processes into their mature counterparts, including RT, IN, and PR [22–27].”
BackgroundInfluentialHIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00611-20 · Cited by 32
“The G140S/Q148H double mutant is a signature RAL-resistant mutant (9) that also arises in response to treatment with the latest FDA-approved INSTIs.”
BackgroundThe Role of Allylic Strain for Conformational Control in Medicinal Chemistry
Zhao, H., Brånalt, J., Perry, M. W. D., & Tyrchan, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00446 · Cited by 31
Bicyclic Hydroxy‐1H‐pyrrolopyridine‐trione Containing HIV‐1 Integrase Inhibitors
Zhao, X. Z., Maddali, K., Métifiot, M., Smith, S. J., Vu, B. C., Marchand, C., Hughes, S. H., Pommier, Y. G., & Burke, T. R. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01270.x · Cited by 29
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations
Varadarajan, J., McWilliams, M. J., & Hughes, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305066110 · Cited by 29
Integration of retroviral vectors
Gabriel, R., Schmidt, M., & Kalle, C. V. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.006 · Cited by 39
Cheung, S., Ma, L., Chan, P. H. W., Hu, H.-L., Mayor, T., Chen, H., & Measday, V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.686840 · Cited by 29
“561 515 422 IN-G (1−422; 515-561) IN-B (422-636) IN-D (1-515)”
BackgroundThe elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet
Marchand, C. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685653 · Cited by 29
“Raltegravir was co-crystallized with the integrase of the prototype foamy virus (PFV) in the presence of retroviral DNA and shown to bind in the active site of the enzyme [7].”
BackgroundIntegrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
Nair, V., & Okello, M. O. (2015) · Molecules · doi:10.3390/molecules200712623 · Cited by 28
“Molecular modeling of the crystal structure of prototype foamy virus (PFV) integrase intasome (PDB code 3OYA) [15,60] with compound 96 docked within the catalytic site was achieved by using the Surflex-Dock package within Sybyl-X [Sybyl-X1.”
MethodAdvances in the development of HIV integrase strand transfer inhibitors
Wang, Y., Gu, S., He, Q., & Fan, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113787 · Cited by 29
Sites of retroviral DNA integration: From basic research to clinical applications
Serrao, E., & Engelman, A. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1102859 · Cited by 36
“…(depicted for HIV-1 in Figure 1) begins as units of IN within the viral preintegration complex (PIC) multi- merize upon the nascent vDNA termini to form the intasome, the IN–vDNA complex from wherein IN catalyzes integration (Chen et al., 1999; Hare et al., 2010, 2012; Li et al., 2006).”
BackgroundSelf-citationRetroviral Integrase: Then and Now
Andrake, M., & Skalka, A. M. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055043 · Cited by 38
Yang, F., Zheng, G., Fu, T., Li, X., Tu, G., Li, Y., Yao, X., Xue, W., & Zhu, F. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp01843j · Cited by 30
Huang, W., Frantzell, A., Fransen, S., & Petropoulos, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00204-13 · Cited by 30
Homology Model-Guided 3D-QSAR Studies of HIV-1 Integrase Inhibitors
Sharma, H., Cheng, X., & Buolamwini, J. K. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200485a · Cited by 29
Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
Rogers, L. C., Obasa, A. E., Jacobs, G. B., Sarafianos, S. G., Sönnerborg, A. B., Neogi, U., & Singh, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01754 · Cited by 33
Corvaglia, V., Carbajo, D., Prabhakaran, P., Ziach, K., Mandal, P. K., Santos, V. D. O., Legeay, C., Vogel, R., Parissi, V., Pourquier, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz352 · Cited by 32
“Next steps will be to determine the structural requirements for these foldamers to achieve stronger and more selective inhibition, a process that would require the use of crystal structure data (34,35) as well as molecular modelling.”
Metal-based strategies for the fight against COVID-19
Li, H., Yuan, S., Wei, X., & Sun, H. (2022) · Chemical Communications · doi:10.1039/d2cc01772e · Cited by 27
Discovery of novel inhibitors of LEDGF/p75-IN protein–protein interactions
Sanchez, T. W., Debnath, B., Christ, F., Otake, H., Debyser, Z., & Neamati, N. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.12.012 · Cited by 27
Carayon, K., Leh, H., Henry, E., Simon, F., Mouscadet, J. F., & Deprez, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq087 · Cited by 35
“In the structure of the PFV-1 IN–viral DNA complex, the N-terminal domain is also involved in the interaction with DNA (7).”
BackgroundInfluentialLigand-Based Virtual Screening in a Search for Novel Anti-HIV-1 Chemotypes
Kurczyk, A., Warszycki, D., Musioł, R., Kafel, R., Bojarski, A. J., & Polański, J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00295 · Cited by 30
Hajimahdi, Z., Zabihollahi, R., Aghasadeghi, M. R., Ashtiani, S. H., & Zarghi, A. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1631-x · Cited by 26
Tang, J. Y., Kirby, K. A., Huber, A. D., Casey, M. C., Ji, J., Wilson, D. J., Sarafianos, S. G., & Wang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.01.041 · Cited by 27
“This is not surprising as inhibition of INSTminimally requires a chelating triad and a hydrophobic aromatic group, typically a fluorobenzyl group [18].”
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors
Zhao, X. Z., Maddali, K., Smith, S. J., Métifiot, M., Johnson, B. C., Marchand, C., Hughes, S. H., Pommier, Y. G., & Burke, T. R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.088 · Cited by 27
Moss, L., Wagner, D. S., Kanaoka, E., Olson, K. L., Yueh, Y. L., & Bowers, G. D. (2014) · Xenobiotica · doi:10.3109/00498254.2014.942409 · Cited by 28
“Dolutegravir (S/GSK1349572) is an unboosted, two-metal binding HIV-1 integrase inhibitor that preferentially blocks the strand transfer step in the integration of viral DNA into the host chromosome (Hare et al., 2010a,b, 2011).”
BackgroundDesimmie, B. A., Demeulemeester, J., Suchaud, V., Taltynov, O., Billamboz, M., Lion, C. J., Bailly, F., Strelkov, S. V., Debyser, Z., Cotelle, P., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000426 · Cited by 28
Serial number tagging reveals a prominent sequence preference of retrotransposon integration
Chatterjee, A. G., Esnault, C., Guo, Y., Hung, S., McQueen, P. G., & Levin, H. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku534 · Cited by 27
“The preferred nucleotides flanking Tf1 s -neo inserts formed a palindrome, a pattern observed with other integrating elements that is thought to be due to stabilizing contacts between the IN and target DNA (4,8,23–26).”
InfluentialRetrotransposon targeting to RNA polymerase III-transcribed genes
Cheung, S., Manhas, S., & Measday, V. (2018) · Mobile DNA · doi:10.1186/s13100-018-0119-2 · Cited by 28
“Structural studies of the prototype foamy virus (PFV) intasome, a homotetramer of PFV-IN, attached to a nucleosome have revealed striking similarity to the nucleosome data from the Ty1 genome-wide mapping studies [40, 49].”
The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors
Velthuisen, E. J., Johns, B. A., Temelkoff, D. P., Brown, K. W., & Danehower, S. C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.038 · Cited by 29
Structural and sequencing analysis of local target DNA recognition by MLV integrase
Aiyer, S., Rossi, P., Malani, N., Schneider, W. M., Chandar, A., Bushman, F. D., Montelione, G. T., & Roth, M. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv410 · Cited by 25
“Additionally, both the prototype foamy virus (PFV) IN and the MLV IN encode an N-terminal extension domain (NED) within the NTD that is not conserved in the human immunodeficiency virus -1 (HIV-1) IN (6).”
BackgroundMethodInfluentialXue, W., Qi, J., Yang, Y., Jin, X., Liu, H., & Yao, X. (2012) · Molecular BioSystems · doi:10.1039/c2mb25114k · Cited by 26
HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01035-18 · Cited by 27
“Currently, all FDA-approved IN inhibitors target the ST reaction, and these compounds are, for that reason, called IN ST inhibitors (INSTIs) (3, 4).”
BackgroundVeselovsky, A. V., Zharkova, M. S., Poroikov, V., & Nicklaus, M. C. (2014) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2014.898689 · Cited by 25
“The recently solved structures of IN of the prototype foamy virus con fi rm this hypothesis [51].”
BackgroundComparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors
Gupta, P. K., Garg, P., & Roy, N. (2011) · Molecular Diversity · doi:10.1007/s11030-011-9304-7 · Cited by 27
“As evident from reported data [22,24,26,43], the interactions”
BackgroundResultVandurm, P., Guiguen, A., Cauvin, C., Georges, B., Van, K. L., Michaux, C., Cardona, C., Mbemba, G., Mouscadet, J. F., Hevesi, L., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.028 · Cited by 25
Reigadas, S., Masquelier, B., Calmels, C., Laguerre, M. S., Lazaro, E., Vandenhende, M. A., Neau, D., Fleury, H. J., & Andréola, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00071-11 · Cited by 27
“Recently, the crystal structure of full-length IN from the prototype foamy virus (PFV) in complex with its cognate DNA was reported (15).”
BackgroundMethodThe Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles
Johnson, M. M., Jones, C. E., & Clark, D. N. (2022) · Viruses · doi:10.3390/v15010107 · Cited by 34
Structural Properties of HIV Integrase·Lens Epithelium-derived Growth Factor Oligomers
Gupta, K., Diamond, T., Hwang, Y., Bushman, F., & Van Duyne, G. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.114413 · Cited by 24
Crosby, I. T., Bourke, D. G., Jones, E. D., de Bruyn, P. J., Rhodes, D., Vandegraaff, N., Cox, S. W., Coates, J. A. V., & Robertson, A. D. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.105 · Cited by 24
Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
Lampiris, H. W. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.157 · Cited by 27
Structural role of the flanking DNA in mariner transposon excision
Dornan, J., Grey, H., & Richardson, J. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv096 · Cited by 30
“previously determined transpososome and intasome structures (11-14).”
Li, X., Koh, Y., & Engelman, A. (2012) · Journal of Virology · doi:10.1128/jvi.06386-11 · Cited by 24
“Results of biochemical experiments have indicated that a tetramer of HIV-1 IN catalyzes the concerted integration of two vDNA ends (46, 51, 71, 92), findings that are consistent with recent X-ray crystal structures of functional prototype foamy virus (PFV) IN-vDNA complexes or intasomes (52, 82).”
ResultSelf-citationHow mouse RAG recombinase avoids DNA transposition
Chen, X., Cui, Y., Wang, H., Zhou, Z. H., Gellert, M. F., & Yang, W. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0366-z · Cited by 25
Suchaud, V., Bailly, F., Lion, C. J., Calmels, C., Andréola, M., Christ, F., Debyser, Z., & Cotelle, P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500109z · Cited by 24
Cryo-EM structure of mouse RAG1/2 PRC complex (DNA1)
Chen, X., Cui, Y., Zhou, Z. H., Yang, W., & Gellert, M. F. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6oen/pdb · Cited by 24
The preclinical discovery and development of dolutegravir for the treatment of HIV
Bailly, F., & Cotelle, P. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1064896 · Cited by 26
“Following the excellent paper issued from the Engelman/ Cherepanov collaboration [19], structural comparisons between raltegravir, elvitegravir and dolutegravir have been undertaken using X-ray crystallographic structures obtained by soaking these drugs with wild-type or mutant PFV intasomes [29].”
BackgroundMethodEfavirenz Enhances HIV-1 Gag Processing at the Plasma Membrane through Gag-Pol Dimerization
Sudo, S., Haraguchi, H., Hirai, Y., Gatanaga, H., Sakuragi, J.-I., Momose, F., & Morikawa, Y. (2013) · Journal of Virology · doi:10.1128/jvi.02306-12 · Cited by 22
“To date, there are no structural data for PR-RT or full-length Pol precursors, and only individual domain oligomers, such as PR homodimers (5, 6), RT heterodimers (58), and IN homotetramers (59, 60), have been solved by nuclear magnetic resonance and crystallography.”
BackgroundRetroviral DNA Transposition: Themes and Variations
Skala, A. M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0005-2014 · Cited by 24
Pandey, K. K., Bera, S., Vora, A. C., & Grandgenett, D. P. (2010) · Biochemistry · doi:10.1021/bi100514s · Cited by 22
“Another study revealed that the terminal 30-GT occupies the active site in closed conformation and the active site is left open immediately after 30-processing and is accessible for binding STI (20, 42).”
BackgroundInfluentialSirous, H., Fassihi, A., Brogi, S., Campiani, G., Christ, F., Debyser, Z., Gemma, S., Butini, S., Chemi, G., Grillo, A., et al. (2018) · Medicinal Chemistry · doi:10.2174/1573406415666181219113225 · Cited by 24
Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors
Carcelli, M., Rogolino, D., Sechi, M., Rispoli, G., Fisicaro, E., Compari, C., Grandi, N., Corona, A., Tramontano, E., Pannecouque, C. C., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.055 · Cited by 23
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors
Zhao, X. Z., Maddali, K., Métifiot, M., Smith, S. J., Vu, B. C., Marchand, C., Hughes, S. H., Pommier, Y. G., & Burke, T. R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.047 · Cited by 23
Solution Conformation and Dynamics of the HIV-1 Integrase Core Domain
Fitzkee, N. C., Masse, J. E., Shen, Y., Davies, D. R., & Bax, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113407 · Cited by 29
Hassounah, S. A., Mésplède, T., Quashie, P. K., Oliveira, M., Sandstrom, P. A., & Wainberg, M. A. (2014) · Journal of Virology · doi:10.1128/jvi.00947-14 · Cited by 26
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
Engelman, K. D., & Engelman, A. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00157 · Cited by 27
Self-citationSeo, B., Uchil, V. R., Okello, M. O., Mishra, S. K., Ma, X., Nishonov, M., Shu, Q., Chi, G., & Nair, V. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2001246 · Cited by 22
Hu, J., He, H.-Q., Tang, D., Guo-feng, S., Zhang, Y., Fan, J., & Chang, S. (2012) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2012.709458 · Cited by 22
“Figure 3(D) gives the correlation result between the value of RMSF from MD simulations and that of the corresponding experimental B-factor from chain A of 3L2T crystal structure (Hare et al., 2010).”
BackgroundMethodResultInfluentialPennington, M. R., Fort, M. W., Ledbetter, E. C., & de Walle, G. R. V. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000451 · Cited by 22
The free energy landscape of retroviral integration
Vanderlinden, W., Brouns, T., Walker, P. U., Kolbeck, P. J., Milles, L. F., Ott, W., Nickels, P. C., Debyser, Z., & Lipfert, J. (2019) · Nature Communications · doi:10.1038/s41467-019-12649-w · Cited by 21
Resistance to inhibitors of the human immunodeficiency virus type 1 integration
Hazuda, D. J. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70103-3 · Cited by 25
Ebina, H., Kanemura, Y., Suzuki, Y., Urata, K., Misawa, N., & Koyanagi, Y. (2012) · Virology · doi:10.1016/j.virol.2012.02.004 · Cited by 22
“In addition, the binding interface of IN and LEDGF/p75 does not overlap with the active site of IN inhibitors (Hare et al., 2010; Michel et al., 2009).”
BackgroundHIVToolbox, an Integrated Web Application for Investigating HIV
Sargeant, D. P., Deverasetty, S., Luo, Y., Baleta, A. V., Zobrist, S., Rathnayake, V. R., Russo, J. C., Vyas, J., Muesing, M. A., & Schiller, M. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020122 · Cited by 22
“The TN5 transposase has a different tetramer structure and the PFV IN and may also have a structure of its active tetramer that is distinct from HIV-1 IN [36,37].”
BackgroundInfluentialLuca, L. D., Gitto, R., Christ, F., Ferro, S., Grazia, S. D., Morreale, F. E., Debyser, Z., & Chimirri, A. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.07.005 · Cited by 23
The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency
Crignis, E. D., & Mahmoudi, T. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.006 · Cited by 24
“Over the years, the establishment of in vitro systems able to reproduce the integration reaction has led to significant advancements in understanding the molecular basis of HIV-1 DNA integration (Hare et al., 2010; Craigie and Bushman, 2014).”
BackgroundA safety evaluation of raltegravir for the treatment of HIV
Buckley, R. D. M., Montejano, R., Stella-Ascariz, N., & Arribas, J. R. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1411903 · Cited by 25
Metadata
- Authors
- Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P.
- Affiliations
- Imperial College London (GB)
- The University of Queensland (AU)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Cherepanov, Peter
- Venue
- Nature
- Published
- 2010-01-31
- Volume
- 464
- Issue
- 7286
- Pages
- 232-236
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2837123
- OpenAlex
- W2025344323
- Cited by
- 678
- References
- 50
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 31 · 2020: 29 · 2019: 38 · 2018: 33 · 2017: 31 · 2016: 43 · 2015: 53 · 2014: 49 · 2013: 68 · 2012: 79
- FWCI
- 60.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Diamond Light Source
- Medical Research Council
- National Institute of Allergy and Infectious Diseases (R01AI070042, P30AI060354)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retroviral integrase, intasome, DNA strand transfer, HIV-1 integrase, integrase strand transfer inhibitors, raltegravir, elvitegravir, antiretroviral drug development, viral DNA integration, protein-DNA interactions
- MeSH terms
- DNA, Viral, Models, Molecular, Retroviridae, HIV-1, Protein Structure, Tertiary, Integrases, Catalytic Domain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.